Journal Mobile Options
Table of Contents
Vol. 10, No. 4, 2003
Issue release date: July–August 2003
J Biomed Sci 2003;10:361–366

A Light in Multidrug Resistance: Photodynamic Treatment of Multidrug-Resistant Tumors

Capella M.A.M. · Capella L.S.
aInstituto de Biofísica Carlos Chagas Filho, bDepartamento de Bioquímica Médica, Universidade Federal do Rio de Janeiro, cDepartamento de Clínica Médica, Universidade do Rio de Janeiro, Rio de Janeiro, Brasil

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The major drawback of cancer chemotherapy is the development of multidrug-resistant (MDR) tumor cells, which are cross-resistant to a broad range of structurally and functionally unrelated agents, making it difficult to treat these tumors. In the last decade, a number of authors have studied the effects of photodynamic therapy (PDT), a combination of visible light with photosensitizing agents, on MDR cells. The results, although still inconclusive, have raised the possibility of treating MDR tumors by PDT. This review examines the growing literature concerning the responses of MDR cells to PDT, while stressing the need for the development of new photosensitizers that possess the necessary characteristics for the photodynamic treatment of this class of tumor.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Blum MF: Photodynamic Action and Diseases Caused by Light. New York, Reinhold, 1941.
  2. Capella M, Coelho AM, Menezes S. Effect of glucose on photodynamic action of methylene blue in Escherichia coli cells. Photochem Photobiol 64:205–210;1996.
  3. Dellinger M, Moreno G, Salet C, Tapiero H, Lampidis TJ. Cytotoxic and photodynamic effects of Photofrin on sensitive and multidrug-resistant Friend leukaemia cells. Int J Radiat Biol 62:735–741;1992.
  4. Diamond I, McDonagh AF, Wilson CB, Granelli SG, Nielsen S, Jaenicke R. Photodynamic therapy of tumors. Lancet ii:1175–1177;1973.
  5. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. Photodynamic therapy (review). J Natl Cancer Inst 90:889–905;1998.
  6. Fojo AT, Akiyama S-I, Gottesman MM, Pastan I. Reduced drug accumulation in multiple drug-resistant human KB carcinoma cell lines. Cancer Res 45:3002–3007;1985.
  7. Ford JM, Prozialeck WC, Hait WN. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 35:105–115;1989.
  8. Foster TH, Hartley DF, Nichols MG, Hilf R. Fluence rate effects in photodynamic therapy of multicell tumor spheroids. Cancer Res 53:1249–1254;1993.
  9. Gibson SL, Al-Shawi MK, Senior AE, Hile R. Inhibition of the ATPase activity of P-glycoprotein by porphyrin photosensitization of multidrug-resistant cells in vitro. Photochem Photobiol 61:390–396;1995.
  10. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427;1993.
  11. Gray MJ, Lipson R, Maeck JV, Parker L, Romeyn D. Use of hematoporphyrin derivative in detection and management of cervical cancer. Am J Obstet Gynecol 99:766–771;1967.
  12. Gulati SC, Lemoli RM, Igarashi T, Atzpodien J. Newer options for treating drug-resistant (MDR+) cancer cells using photoradiation therapy. Leuk Lymphoma 12:427–433;1994.
  13. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 55:145–157;1992.
  14. Holandino C, Capella MAM, Angluster J, Silva-Filho FC, Menezes S, Alviano C. Cell surface alterations induced by methylene blue and direct electric current in Escherichia coli. Indian J Biochem Biophys 35:284–290;1998.
  15. Jirsa M Jr, Poucková P, Dolezal J, Pospisil J, Jirsa M. Hyperbaric oxygen and photodynamic therapy in tumor-bearing nude mice. Eur J Cancer 27:109;1991.
  16. Juranka PF, Zastawny RL, Ling V. P-glycoprotein: Multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 3:2583–2592;1989.
  17. Kanofsky JR, Sima PD. Preferential cytotoxicity for multidrug-resistant K562 cells using the combination of a photosensitizer and a cyanine dye. J Photochem Photobiol B 54:136–144;2000.

    External Resources

  18. Kessel D, Erickson C. Porphyrin photosensitization of multidrug resistant cell types. Photochem Photobiol 55:397–399;1992.
  19. Kessel D, Luo Y, Deng Y, Cang CK. The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Photochem Photobiol 65:422–426;1997.
  20. Kessel D, Woodburn K. Selective photodynamic inactivation of a multidrug transporter by a cationic photosensitizing agent. Br J Cancer 71:306–310;1995.
  21. Kessel D, Woodburn K, Henderson BW, Chang CK. Sites of photodamage in vivo and in vitro by a cationic porphyrin. Photochem Photobiol 62:875–881;1995.
  22. Kuo MT, Bao J, Furuichi M, Yamane Y, Gomi A, Savaraj N, Masuzawa T, Ishikawa T. Frequent coexpression of MRP/GS-X pump and gamma-glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues. Biochem Pharmacol 55:605–615;1998.
  23. Kusuzaki K, Minami G, Takeshita H, Murata H, Hashiguchi S, Nozaki T, Ashihara T, Hirasawa Y. Photodynamic inactivation with acridine orange on a multidrug-resistant mouse osteosarcoma cell line. Jpn J Cancer Res 91:439–445;2000.
  24. Laustriat G. Molecular mechanisms of photosensitization. Biochimie 68:771–778;1986.
  25. Ledoux-Lebard. Action de la lumière sur la toxicité de l’éosine et de quelques autres substances pour les paramècies. Ann Int Pasteur 16:587–594;1902.
  26. Li W, Zhang WJ, Ohnishi K, Yamada I, Ohno R, Hashimoto K. 5-Aminolaevulinic acid-mediated photodynamic therapy in multidrug resistant leukemia cells. J Photochem Photobiol B 60:79–86;2001.
  27. Link EM, Carpenter RN, Hansen G: 211At-methylene blue for targeted radiotherapy of human melanoma xenografts: Dose fractionation in the treatment of cutaneous tumours. Eur J Cancer 32A:1240–1247;1996.
  28. Lipson RL, Baldes EJ, Gray MJ. Hematoporphyrin derivative for detection and management of cancer. Cancer 20:2255–2257;1967.
  29. Menezes S, Capella MAM, Caldas LR. Photodynamic action of methylene blue: Repair and mutation in Escherichia coli. J Photochem Photobiol B 5:505–517;1990.
  30. Moan J, Sommer S. Oxygen dependence of the photosensitizing effect of hematoporphyrin derivative in NHK 3025 cells. Cancer Res 45:1608–1610;1985.
  31. Mohr H, Bachmann B, Klein-Struckmeier A, Lambrecht B. Virus inactivation of blood products by phenothiazine dyes and light. Photochem Photobiol 65:441–445;1997.
  32. Müller M, Meyer C, Zaman GJR, Borst P, Scheper RJ, Mulder NH, De Vries EGE, Jansen PLM. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 91:13033–13037;1994.
  33. Müller-Breitkreutz K, Mohr H. Hepatitis C and human immunodeficiency virus RNA degradation by methylene blue/light treatment of human plasma. J Med Virol 56:239–245;1998.
  34. Mulroney CM, Gluck S, Ho AD. The use of photodynamic therapy in bone marrow purging. Semin Oncol 21(6 suppl 15):24–27;1994.
  35. Orth K, Ruck A, Beck G, Stanescu A, Beger HG. Photodynamic therapy of small adenocarcinomas with methylene blue (in German). Chirurg 66:1254–1257;1995.
  36. Orth K, Ruck A, Stanescu A, Beger HG. Intraluminal treatment of inoperable oesophageal tumours by intralesional photodynamic therapy with methylene blue. Lancet 345:519–520;1995.

    External Resources

  37. Orth K, Russ D, Beck G, Ruck A, Beger HG. Photochemotherapy of experimental colonic tumours with intra-tumorally applied methylene blue. Langenbecks Arch Surg 383:276–281;1998.
  38. Peng Q, Moan J, Nesland JM. Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Ultrastruct Pathol 20:109–129;1996.
  39. Purkiss SF, Grahn MF, Turkish M, Macey MG, Williams NS. In vitro modulation of haematoporphyrin derivative photodynamic therapy on colorectal carcinoma multicellular spheroids by verapamil. Br J Surg 79:120–125;1992.
  40. Purkiss SF, Grahn MF, Williams NS. Haematoporphyrin derivative-photodynamic therapy of colorectal carcinoma, sensitized using verapamil and adriamycin. Surg Oncol 5:169–175;1996.
  41. Raab VO. Uber dir Wirkung fluoreszierender Stoffe auf Infusorien. Z Biol 39:524–546;1900.
  42. Ramu A, Ramu N. Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother 30:165–173;1992.
  43. Ruck A, Heckelsmiller K, Akgun N, Beck G, Kunzi-Rapp K, Schick E, Steiner R. Nonlinear dynamics of intracellular methylene blue during light activation of cell cultures. Photochem Photobiol 66:837–841;1997.
  44. Ruck A, Kollner T, Dietrich A, Strauss W, Schneckenburger H. Fluorescence formation during photodynamic therapy in the nucleus of cells incubated with cationic and anionic water-soluble photosensitizers. J Photochem Photobiol B 12:403–412;1992.
  45. Sattler U, Calsou P, Boiteux S, Salles B. Detection of oxidative base DNA damage by a new biochemical assay. Arch Biochem Biophys 376:26–33;2000.
  46. Schneider JE, Price S, Maidt L, Gatteridge JMC, Floyd RA: Methylene blue plus light mediates 8-hydroxy-2′-deoxyguanosine formation in DNA preferentially over strand breakage. Nucleic Acids Res 18:631–635;1990.
  47. Schneider JE Jr, Tabatabaie T, Maidt L, Smith RH, Nguyen X, Pye Q, Floyd RA. Potential mechanisms of photodynamic inactivation of virus by methylene blue. I. RNA-protein crosslinks and other oxidative lesions in Q beta bacteriophage. Photochem Photobiol 67:350–357;1998.
  48. Sibata CH, Colussi VC, Oleinick NL, Kinsella TJ. Photodynamic therapy: A new concept in medical treatment. Braz J Med Biol Res 33:869–880;2000.
  49. Sitnik TM, Hampton JA, Henderson BW. Reduction of tumor oxygenation during and after photodynamic therapy in vivo: Effects of fluence rate. Br J Cancer 77:1386–1394;1998.
  50. Slater LM, Sweet P, Stupecky M, Wetzel MW, Gupta S. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br J Cancer 54:235–238;1986.
  51. Spikes JD, Macknight ML. Photodynamic effects on molecules of biological importance: Amino acids, peptides and proteins. Res Prog Org Biol Med Chem 3:124–136;1972.
  52. Teiten MH, Bezdetnaya L, Merlin JL, Bour-Dill C, Pauly ME, Dicato M, Guillemin F. Effect of meta-tetra(hydroxyphenyl)chlorin (mTHPC)-mediated photodynamic therapy on sensitive and multidrug-resistant human breast cancer cells. J Photochem Photobiol B 62:146–152;2001.

    External Resources

  53. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735–7738;1987.
  54. Trindade GS, Capella MAM, Capella LS, Affonso-Mitidieri OR, Rumjanek VM. Differences in sensitivity to UVC, UCB and UVA radiation of a multidrug-resistant cell line overexpressing P-glycoprotein. Photochem Photobiol 69:694–699;1999.
  55. Trindade GS, Farias SLA, Rumjanek VM, Capella MAM. Methylene blue reverts multidrug resistance: Sensitivity of multidrug resistant cells to this dye and its photodynamic action. Cancer Lett 151:161–167;2000.

    External Resources

  56. Tromberg BJ, Orenstein A, Kimel S, Barker SJ, Hyatt J, Nelson JS, Berns MW. In vivo tumor oxygen tension measurements for the evaluation of the efficiency of photodynamic therapy. Photochem Photobiol 52:375–385;1990.
  57. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia ‘in vivo’ and ‘in vitro’ through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967–1972;1981.
  58. Vandoni RE, Cuttat JF, Wicky S, Suter M: CT-guided methylene-blue labelling before thoracoscopic resection of pulmonary nodules. Eur J Cardiothorac Surg 14:265–270;1998.
  59. Wainwright M, Phoenix DA, Burrow SM, Waring J. Cytotoxicity and adjuvant activity of cationic photosensitizers in a multidrug resistant cell line. J Chemother 11:61–68;1999.
  60. Weishaupt KR, Gomer CJ, Dougherty TJ. Identification of singlet oxygen as the cytotoxic agent in cancer photoinactivation of a murine tumor. Cancer Res 36:2326–2329;1976.
  61. Zaidi SIA, Oleinick NL, Zaim MT, Mukhtar H. Apoptosis during photodynamic therapy-induced ablation of RIF-1 tumors in C3H mice: Electron microscopic, histopathologic and biochemical evidence. Photochem Photobiol 58:771–776;1993.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50